Lutetium-177 labeled peptides: The European institute of oncology experience

Angela Carollo, Stefano Papi, Marco Chinol

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive tumors. Partial remission rates up to 30% have been documented as well as significant improvements in quality of life and survival. This treatment takes advantage of the high specific binding of the radiolabeled peptide to somatostatin receptors overexpressed by the tumors thus being more effective on the tumor cells with less systemic side-effects. The development of macrocyclic chelators conjugated to peptides made possible the stable binding with various radionuclides. In particular 177Lu features favourable physical characteristics with a half-life of 6.7 days, emission of β-with energy of 0.5 MeV for treatment and γ-emissions suitable for imaging. The present contribution describes the learning process achieved at the European Institute of Oncology (IEO) since the first application of 90Y labeled peptides to the therapy of neuroendocrine tumors back in 1997. Continuous improvements led to the preparation of a safe 177Lu labeled peptide for human use. Our learning curve began with the identification of the optimal characteristics of the isotope paying attention to its chemical purity and specific activity along with the optimization of the parameters involved in the radiolabeling procedure. Also the radiation protection issues have been improved along the years and recently more and more attention has been devoted to the pharmaceutical aspects involved in the preparation. The overall issue of the quality has now been completed by drafting an extensive documentation with the goal to deliver a safe and reliable product to our patients.

Original languageEnglish
Pages (from-to)19-32
Number of pages14
JournalCurrent Radiopharmaceuticals
Volume9
Issue number1
Publication statusPublished - Jan 1 2016

Fingerprint

Lutetium
Somatostatin Receptors
Peptides
Radioisotopes
Neoplasms
Radiation Protection
Learning Curve
Peptide Receptors
Neuroendocrine Tumors
Therapeutics
Chelating Agents
Somatostatin
Isotopes
Documentation
Half-Life
Quality of Life
Learning
Survival
Pharmaceutical Preparations

Keywords

  • Lu-DOTATATE
  • DOTA-peptide
  • GEP-NETs
  • Lutetium-177
  • PRRT
  • Quality control
  • β-emitter

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pharmacology

Cite this

Lutetium-177 labeled peptides : The European institute of oncology experience. / Carollo, Angela; Papi, Stefano; Chinol, Marco.

In: Current Radiopharmaceuticals, Vol. 9, No. 1, 01.01.2016, p. 19-32.

Research output: Contribution to journalArticle

@article{f1e5fc088f754807ae2bdf357060935b,
title = "Lutetium-177 labeled peptides: The European institute of oncology experience",
abstract = "Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive tumors. Partial remission rates up to 30{\%} have been documented as well as significant improvements in quality of life and survival. This treatment takes advantage of the high specific binding of the radiolabeled peptide to somatostatin receptors overexpressed by the tumors thus being more effective on the tumor cells with less systemic side-effects. The development of macrocyclic chelators conjugated to peptides made possible the stable binding with various radionuclides. In particular 177Lu features favourable physical characteristics with a half-life of 6.7 days, emission of β-with energy of 0.5 MeV for treatment and γ-emissions suitable for imaging. The present contribution describes the learning process achieved at the European Institute of Oncology (IEO) since the first application of 90Y labeled peptides to the therapy of neuroendocrine tumors back in 1997. Continuous improvements led to the preparation of a safe 177Lu labeled peptide for human use. Our learning curve began with the identification of the optimal characteristics of the isotope paying attention to its chemical purity and specific activity along with the optimization of the parameters involved in the radiolabeling procedure. Also the radiation protection issues have been improved along the years and recently more and more attention has been devoted to the pharmaceutical aspects involved in the preparation. The overall issue of the quality has now been completed by drafting an extensive documentation with the goal to deliver a safe and reliable product to our patients.",
keywords = "Lu-DOTATATE, DOTA-peptide, GEP-NETs, Lutetium-177, PRRT, Quality control, β-emitter",
author = "Angela Carollo and Stefano Papi and Marco Chinol",
year = "2016",
month = "1",
day = "1",
language = "English",
volume = "9",
pages = "19--32",
journal = "Current Radiopharmaceuticals",
issn = "1874-4710",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Lutetium-177 labeled peptides

T2 - The European institute of oncology experience

AU - Carollo, Angela

AU - Papi, Stefano

AU - Chinol, Marco

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive tumors. Partial remission rates up to 30% have been documented as well as significant improvements in quality of life and survival. This treatment takes advantage of the high specific binding of the radiolabeled peptide to somatostatin receptors overexpressed by the tumors thus being more effective on the tumor cells with less systemic side-effects. The development of macrocyclic chelators conjugated to peptides made possible the stable binding with various radionuclides. In particular 177Lu features favourable physical characteristics with a half-life of 6.7 days, emission of β-with energy of 0.5 MeV for treatment and γ-emissions suitable for imaging. The present contribution describes the learning process achieved at the European Institute of Oncology (IEO) since the first application of 90Y labeled peptides to the therapy of neuroendocrine tumors back in 1997. Continuous improvements led to the preparation of a safe 177Lu labeled peptide for human use. Our learning curve began with the identification of the optimal characteristics of the isotope paying attention to its chemical purity and specific activity along with the optimization of the parameters involved in the radiolabeling procedure. Also the radiation protection issues have been improved along the years and recently more and more attention has been devoted to the pharmaceutical aspects involved in the preparation. The overall issue of the quality has now been completed by drafting an extensive documentation with the goal to deliver a safe and reliable product to our patients.

AB - Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues has shown encouraging results in various somatostatin receptor positive tumors. Partial remission rates up to 30% have been documented as well as significant improvements in quality of life and survival. This treatment takes advantage of the high specific binding of the radiolabeled peptide to somatostatin receptors overexpressed by the tumors thus being more effective on the tumor cells with less systemic side-effects. The development of macrocyclic chelators conjugated to peptides made possible the stable binding with various radionuclides. In particular 177Lu features favourable physical characteristics with a half-life of 6.7 days, emission of β-with energy of 0.5 MeV for treatment and γ-emissions suitable for imaging. The present contribution describes the learning process achieved at the European Institute of Oncology (IEO) since the first application of 90Y labeled peptides to the therapy of neuroendocrine tumors back in 1997. Continuous improvements led to the preparation of a safe 177Lu labeled peptide for human use. Our learning curve began with the identification of the optimal characteristics of the isotope paying attention to its chemical purity and specific activity along with the optimization of the parameters involved in the radiolabeling procedure. Also the radiation protection issues have been improved along the years and recently more and more attention has been devoted to the pharmaceutical aspects involved in the preparation. The overall issue of the quality has now been completed by drafting an extensive documentation with the goal to deliver a safe and reliable product to our patients.

KW - Lu-DOTATATE

KW - DOTA-peptide

KW - GEP-NETs

KW - Lutetium-177

KW - PRRT

KW - Quality control

KW - β-emitter

UR - http://www.scopus.com/inward/record.url?scp=84949788142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949788142&partnerID=8YFLogxK

M3 - Article

C2 - 25771368

AN - SCOPUS:84949788142

VL - 9

SP - 19

EP - 32

JO - Current Radiopharmaceuticals

JF - Current Radiopharmaceuticals

SN - 1874-4710

IS - 1

ER -